Doxycycline alone clears Mycoplasma genitalium only about 63% of the time, which is not reliable enough to be considered a cure. Instead, current CDC guidelines use doxycycline as the critical first step in a two-stage treatment, where it reduces the bacterial load so a second antibiotic can finish the job. That two-step approach pushes cure rates above 90%.
Why Doxycycline Alone Falls Short
Doxycycline works by blocking the bacteria’s ability to make proteins, which slows its growth and reduces the number of organisms in your body. But M. genitalium is unusually difficult to kill. It lacks a cell wall, which makes it naturally resistant to many common antibiotics like penicillin. And while doxycycline can suppress the infection, it often cannot fully eliminate it.
In clinical data, doxycycline as a standalone treatment cleared the infection in roughly 63% of patients. That means more than one in three people who take only doxycycline will still test positive afterward. Resistance to doxycycline also appears to be increasing over time, which makes monotherapy even less dependable going forward.
The Two-Step Approach That Works
The standard treatment recommended by the CDC starts with seven days of doxycycline taken twice daily. This initial course is not expected to cure the infection on its own. Its purpose is to knock down the bacterial load, making the remaining organisms easier for a second antibiotic to clear. Think of it as softening the target before the finishing blow.
What comes after doxycycline depends on whether the bacteria are resistant to a class of antibiotics called macrolides. If your provider can run resistance testing (more on that below), the results determine your next step:
- If macrolide-susceptible: A four-day course of azithromycin follows the doxycycline week.
- If macrolide-resistant: A seven-day course of moxifloxacin follows instead.
When resistance testing is not available, the default second antibiotic is moxifloxacin for seven days. In Australia, where this resistance-guided approach has been studied extensively, the combined cure rate reached 92%, even in areas where 15% to 20% of infections showed resistance to the follow-up drugs.
Why Resistance Testing Matters
M. genitalium has high rates of macrolide resistance in many parts of the world, which means azithromycin alone fails frequently. Testing the bacteria for resistance mutations before choosing the second antibiotic avoids wasting time on a drug that won’t work. In the U.S., the CDC recommends this resistance-guided approach whenever testing is available.
If your provider does not have access to resistance testing, the guidelines default to the doxycycline-then-moxifloxacin sequence. This is the more conservative path, since moxifloxacin has a higher cure rate (around 85% even without the doxycycline lead-in) and works against macrolide-resistant strains. The tradeoff is that moxifloxacin carries a higher risk of side effects, which is why providers prefer to reserve it for confirmed resistant cases when possible.
What to Expect During Treatment
The full course takes about two weeks. You’ll spend the first seven days on doxycycline, then immediately start the second antibiotic. Doxycycline is typically well tolerated, though it can cause nausea or sun sensitivity. Taking it with food and avoiding prolonged sun exposure helps.
After finishing both rounds of antibiotics, you’ll need a follow-up test to confirm the infection is gone. This test should happen at least 21 days after completing treatment. Testing too early can produce a false positive because fragments of dead bacteria may still be detectable. The test used is a nucleic acid amplification test (NAAT), the same type used for the initial diagnosis.
If your symptoms improve during the doxycycline phase, that’s a good sign, but it does not mean you can skip the second antibiotic. The bacteria are suppressed, not eliminated. Stopping early increases the risk of the infection bouncing back, potentially with new resistance that makes future treatment harder.
If the First Round Fails
Treatment failure does happen, particularly when resistance testing was not available or when the bacteria carry resistance mutations to both macrolides and the follow-up drug. If your test of cure comes back positive, your provider will reassess and may try the alternative second-line antibiotic you did not receive the first time. For example, if you initially received azithromycin after doxycycline, the next attempt would likely use moxifloxacin.
Sexual partners should also be tested and treated. Reinfection from an untreated partner is one of the most common reasons people test positive again after completing their own treatment. Avoiding sexual contact until both you and your partner have completed treatment and confirmed clearance prevents this cycle.